Sandra E. Poole
Directeur/Membre du Conseil chez TRAVERE THERAPEUTICS, INC.
Fortune : 126 665 $ au 30/04/2024
Postes actifs de Sandra E. Poole
Sociétés | Poste | Début | Fin |
---|---|---|---|
TRAVERE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/05/2019 | - |
Independent Dir/Board Member | 13/05/2019 | - | |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 27/06/2019 | - |
Mythic Therapeutics, Inc.
Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Directeur des opérations | 01/07/2020 | - |
Historique de carrière de Sandra E. Poole
Anciens postes connus de Sandra E. Poole
Sociétés | Poste | Début | Fin |
---|---|---|---|
VALNEVA | Directeur/Membre du Conseil | 30/06/2017 | 17/06/2020 |
Independent Dir/Board Member | 30/06/2017 | 17/06/2020 | |
CANDEL THERAPEUTICS, INC. | Directeur des opérations | 10/01/2020 | 01/03/2020 |
LOGICBIO THERAPEUTICS, INC. | Directeur des opérations | 01/04/2018 | 31/03/2019 |
S. Poole Consulting LLC
S. Poole Consulting LLC Miscellaneous Commercial ServicesCommercial Services S. Poole Consulting LLC provides business consulting services. The private company is based in Boston, MA. | Corporate Officer/Principal | 01/08/2016 | 01/03/2018 |
IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 17/09/2014 | 01/01/2017 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/02/1999 | 01/09/2014 |
Formation de Sandra E. Poole
The University of Waterloo | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Canada | 2 |
France | 2 |
Opérationnelle
Chief Operating Officer | 3 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Sectorielle
Health Technology | 9 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
VALNEVA | Health Technology |
TRAVERE THERAPEUTICS, INC. | Health Technology |
CANDEL THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
S. Poole Consulting LLC
S. Poole Consulting LLC Miscellaneous Commercial ServicesCommercial Services S. Poole Consulting LLC provides business consulting services. The private company is based in Boston, MA. | Commercial Services |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Mythic Therapeutics, Inc.
Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Health Technology |
- Bourse
- Insiders
- Sandra E. Poole
- Expérience